Skip to main content
Clinical Trials/NCT03966976
NCT03966976
Unknown
Phase 4

Comparison Between "Conventional Monitoring" Versus "Monitoring Via Vitaphone" in the Detection of Post Ablation Atrial Arrhythmias of Paroxysmal Atrial Fibrillation

Ramsay Générale de Santé1 site in 1 country20 target enrollmentMarch 15, 2018

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Ramsay Générale de Santé
Enrollment
20
Locations
1
Primary Endpoint
Recurrence rate of AF between 3 and 6 months
Last Updated
6 years ago

Overview

Brief Summary

Atrial fibrillation (AF) is the most common atrial arrhythmia. Ablation of AF is a recent technique, nevertheless, the success rates of ablation vary between 50% and 70% depending on the paroxysmal or persistent nature of AF. These rates are difficult to assess in routine practice because they are based on the recurrence of fibrillation.

The Vitaphone is a non-invasive device, with which the patient can record a single-track ECG as his or her symptoms take place. The plot is then transmitted via the internet to the centre, which can thus diagnose a relapse of AF.

The aim of our study is to correlate the rhythm and symptoms of 20 patients with Vitaphone 6 months after AF ablation and to compare them with 20 other patients receiving conventional monitoring.

Detailed Description

Atrial fibrillation (AF) is the most common atrial arrhythmia in the population and its incidence will increase in the coming years. Ablation of AF is a recent technique, the efficiency of which has considerably increased in recent years. Nevertheless, the success rates of ablation vary between 50% and 70% depending on the paroxysmal or persistent nature of AF. These rates are difficult to assess in routine practice because they are based on the recurrence of fibrillation. This definition of recurrence based on symptoms (palpitations, asthenia, fatigue, shortness of breath, malaise, precordialgia) is widely debated because some patients have asymptomatic AF recidivism, while others experience palpitations that are not due to AF. In this context, studies have been carried out with electrocardiographic recording devices implanted subcutaneously. Given the invasiveness of this monitoring, it is not feasible in current practice. The Vitaphone is a non-invasive device, with which the patient can record a single-track ECG as his or her symptoms take place. The plot is then transmitted via the internet to the centre, which can thus diagnose a relapse of AF. The aim of our study is to correlate the rhythm and symptoms of 20 patients with Vitaphone 6 months after AF ablation and to compare them with 20 other patients receiving conventional monitoring. This is, to our knowledge, the first non-invasive French study using the Vitaphone.

Registry
clinicaltrials.gov
Start Date
March 15, 2018
End Date
September 30, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • AF ablated patient
  • Patient with paroxysmal AF before the procedure
  • Patient with health insurance or beneficiary of a social security scheme
  • Unprotected adult patient
  • Patient having given their consent

Exclusion Criteria

  • Patient having undergone an AF ablation due to persistent AF
  • Unable to understand or handle the Vitaphone alone
  • Failure to participate
  • Pregnant, lactating or parturient women
  • Adult receiving psychiatric care, under legal protection, trusteeship or guardianship, or deprived of liberty by judicial or administrative decision

Outcomes

Primary Outcomes

Recurrence rate of AF between 3 and 6 months

Time Frame: 3 to 6 months

Atrial arrhythmia documented in each arm by either an ECG or Holter or Vitaphone between 3 and 6 months post-ablation of paroxysmal AF and validated by a cardiologist.

Study Sites (1)

Loading locations...

Similar Trials